Want to see FR:ALMIB full AI Analyst Report?
ALMIB Stock Chart & Stats
€0.67
<€0.01(0.15%)
At close: 4:00 PM EDT
€0.67
<€0.01(0.15%)
Day’s Range― - ―
52-Week Range€0.62 - €1.20
Previous CloseN/A
Volume48.65K
Average Volume (3M)268.33K
Market Cap
€55.69M
Enterprise Value€67.72M
Total Cash (Recent Filing)€4.72M
Total Debt (Recent Filing)€12.24M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding77,817,220
10 Day Avg. Volume303,333
30 Day Avg. Volume268,330
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Bulls Say, Bears Say
Bulls Say
Proprietary Biological PlatformAmoéba's Willaertia magna platform represents a differentiated, hard-to-replicate biological asset. Owning a unique active organism and formulation know‑how creates a durable technical moat for biocontrol and biofertilizer products, supporting long‑term product pipeline and niche market positioning even as commercialization scales.
Multiple Scalable Revenue StreamsThe firm can monetize its platform through finished-product sales, licensing, partnerships, and R&D services. This diversified model provides structural optionality: product commercialization, partner-led rollouts and royalties reduce single-channel reliance and enable scale without proportional capex increases.
Signs Of Operational ImprovementAlthough still loss-making, narrowing operating losses, improved free cash flow in 2025 and modest equity recovery indicate early operational stabilization. Sustained execution on costs, manufacturing scale or commercial traction could lengthen runway and improve funding prospects over the coming months.
Bears Say
Revenue CollapseA near‑total loss of revenue in 2025 erodes the company's commercial base and undermines its ability to demonstrate repeatable product demand. Without a restored and diversified revenue stream, long‑term viability and partner confidence are impaired, increasing reliance on non‑operational funding.
Negative Equity And Higher LeverageThree consecutive years of negative equity combined with materially higher debt materially reduce financial flexibility. This structural balance‑sheet weakness heightens refinancing risk, raises funding costs, and constrains the company's ability to invest in scale‑up, registrations or commercial rollouts.
Persistent Cash BurnConsistent negative operating and free cash flows indicate ongoing cash burn and dependency on external financing. Over the medium term this pressures strategic choices, risks dilution, and can delay product registrations or capacity investments if funding access tightens or becomes more expensive.
Amoeba SA News
ALMIB FAQ
What was Amoeba SA’s price range in the past 12 months?
Amoeba SA lowest stock price was €0.62 and its highest was €1.20 in the past 12 months.
What is Amoeba SA’s market cap?
Amoeba SA’s market cap is €55.69M.
When is Amoeba SA’s upcoming earnings report date?
Amoeba SA’s upcoming earnings report date is Sep 24, 2026 which is in 48 days.
How were Amoeba SA’s earnings last quarter?
Amoeba SA released its earnings results on Mar 26, 2026. The company reported -€0.066 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.066.
Is Amoeba SA overvalued?
According to Wall Street analysts Amoeba SA’s price is currently Overvalued.
Does Amoeba SA pay dividends?
Amoeba SA does not currently pay dividends.
What is Amoeba SA’s EPS estimate?
Amoeba SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amoeba SA have?
Amoeba SA has 77,817,220 shares outstanding.
What happened to Amoeba SA’s price movement after its last earnings report?
Amoeba SA reported an EPS of -€0.066 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.112%.
Which hedge fund is a major shareholder of Amoeba SA?
Currently, no hedge funds are holding shares in FR:ALMIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Amoeba SA
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across various fields. These applications are designed to mitigate biological risks in critical areas like water purification, the treatment of human injuries, and safeguarding agricultural crops. Established in 2010, Amoéba S.A. is based in Chassieu, France.